Targets › CMV
4 programs from 4 companies in 11 trials: 5 Phase 2, 5 Phase 1, 1 Phase 3; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on CMV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tobias Feuchtinger | Multivirus (CMV, EBV, AdV)-specific T cells Adoptive transfer of multivirus-specific T cells targeting CMV, EBV, and AdV | CMV, EBV, ADV | Phase 3 | AdV Infection | Mar 2028 |
| City of Hope Medical Center | Multi-peptide CMV-Modified Vaccinia Ankara Vaccine MVA-vectored vaccine expressing CMV peptides; induces immunity to CMV antigens | CMV | Phase 2 | Acute Lymphoblastic Leukemia; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Cytomegaloviral Infection; Accelerated Phase CML, BCR-ABL1 Positive … | Dec 2026 |
| ModernaTX | mRNA-1647 mRNA vaccine expressing CMV antigens | CMV | Phase 2 | Cytomegalovirus Infection | Mar 2027 |
| The Methodist Hospital Research Institute | Valganciclovir Human herpesvirus 1 DNA polymerase inhibitor | CMV | Phase 2 | Brain Cancer Metastatic | May 2028 |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (2) Cytomegalovirus Infection (1) AdV Infection (1) Acute Lymphoblastic Leukemia (1) Cytomegaloviral Infection (1) Accelerated Phase CML, BCR-ABL1 Positive (1) B-Cell Non-Hodgkin Lymphoma (1) High Grade B-Cell Non-Hodgkin's Lymphoma (1) Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive (1) Brain Cancer Metastatic (1)
other (2), small molecule (1)
ModernaTX (1) Tobias Feuchtinger (1) City of Hope Medical Center (1) The Methodist Hospital Research Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.